Luminescent Assay for the Screening of SARS‐CoV‐2 M(Pro) Inhibitors

Since the outbreak of SARS‐CoV‐2 in December 2019 millions of infections have been reported globally. The viral chymotrypsin‐like main protease (M(Pro)) exhibits a crucial role in viral replication and represents a relevant target for antiviral drug development. In order to screen potential M(Pro) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sondag, Daan, Merx, Jona, Rossing, Emiel, Boltje, Thomas J., Löwik, Dennis W. P. M., Nelissen, Frank H. T., van Geffen, Mark, van 't Veer, Cornelis, van Heerde, Waander L., Rutjes, Floris P. J. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401586/
https://www.ncbi.nlm.nih.gov/pubmed/35649961
http://dx.doi.org/10.1002/cbic.202200190
Descripción
Sumario:Since the outbreak of SARS‐CoV‐2 in December 2019 millions of infections have been reported globally. The viral chymotrypsin‐like main protease (M(Pro)) exhibits a crucial role in viral replication and represents a relevant target for antiviral drug development. In order to screen potential M(Pro) inhibitors we developed a luminescent assay using a peptide based probe containing a cleavage site specific for M(Pro). This assay was validated showing IC(50) values similar to those reported in the literature for known M(Pro) inhibitors and can be used to screen new inhibitors.

Ejemplares similares